Determination of residual solvents and investigation of their effect on ampicillin trihydrate crystal structure

Journal of Pharmaceutical and Biomedical Analysis

Volumn 36, Issue 5, 2005, Pages 983-988

  Nojavan, Saeed ^a   Ghassempour, Alireza ^a   Bashour, Yosef ^b   Darbandi, Masoud Khalilian ^b   Ahmadi, Seyyed Hamid ^c  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b Quality Control Lab   (Iran)

^c CHEMISTRY AND CHEMICAL ENGINEERING RESEARCH CENTER OF IRAN   (Iran)

Author keywords

Ampicillin trihydrate; Crystal stability; GC; Residual solvent; XRD

Indexed keywords

AMPICILLIN; DICHLOROMETHANE; SOLVENT;

ARTICLE; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG STABILITY; DRUG STRUCTURE; GAS CHROMATOGRAPHY; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; SOLID STATE; X RAY DIFFRACTION;

AMPICILLIN; CRYSTALLIZATION; SOLVENTS;

EID: 11044234756     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2004.08.031     Document Type: Article

References (33)

1. P. Kolar, W. Shen, A. Tsuboi, and T. Ishikawa Fluid Phase Equilib. 194 2002 771 783
2. C. Reihardt Solvent and Solvent Effects in Organic Chemistry 2nd ed. 1990 VCH-Verlag Weinheim
3. R. Carlson, T. Lundsted, and C. Albano Acta Chem. Scand. B39 1985 79 91
4. S. Yalkowsky Solubility and Solubilization in Aqueous Media 1999 Oxford University Press New York
5. D. Winn, and M.F. Doherty AICHEJ 46 2000 1348 1367
6. J. Saunders Top Drugs: Top Synthetic Routes 2000 Oxford University Press Oxford
7. S. Kojima Impurities: Guideline for Residual Solvents (Q3C) Proceedings of the 4th International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals Brussels, Belgium 1997 July 16-18 (http://www.ich.org/)
8. M. Mosebach, K. Rau, and H. Hffmann Technische Ueberwachung (Duessedorf) 41 2000 17 21
9. J. Roy AAPS Pharm. Scitech. 3 2002 article 6 (http://www. aapspharmscitech.org)
10. Organic Volatile Impurities, the United States Pharmacopoeia 24/National Formulary 19 The United States Pharmacopail Convontion, Rock Vill, MD, 2000.
11. M. Farajzadeh, and A. Mardani Anal. Sci. 18 2002 171 175
12. C. Costin, M. Maria, and B. Gabor J. Pharm. Biomed. 18 1998 623 636
13. C. Costin J. Pharm. Biomed. Anal. 23 2000 197 210
14. A. Michael, X. Bill, and E. William Nucl. Med. Biol. 28 2001 469 471
15. Z. Penton J. High Resol. Chromatogr. 15 1992 329 331
16. D. Eric, and W. Claudia Euro. J. Pharm. Biopharm. 43 1997 215 242
17. M. Kenin, W. Thomas, F. David, and B. John J. Chromatogr. B 686 1996 8595
18. R. Suryanarayanan, and J. Han Thermochim. Acta 329 1999 163 170
19. A. Gregory, F. Robert, and R. Susan Adv. Drug Deliv. Rev. 48 2001 67 90
20. D. Giron Eng. Life Sci. 3 2003 3 21
21. Y. Evgenyi, and G. Zografi J. Pharm. Sci. 85 1996 1137 1141
22. H. Zhu, and D. Grant Int. J. Pharm. 139 1996 33 43
23. H. Jeong, S. UN, H. Jin, and H. Seon Bullk. Korean Soc. 22 2001 925 928
24. P. Doylo, C. Nayler, C. Smith, and R. Stove Nature 191 1961 1091 1092
25. J. Roy, G. Mohammad, and A. Banu Indian Drugs 30 1993 211 219
26. N. Pilar, G. Ana, and M. Pedro Talanta 46 1998 101 109
27. E. Pawelczyk, T. Hermann, M. Zajac, K. Knitter, and B. Smilowski Polish J. Pharmacol. Pharm. 32 1980 47 54
28. J.M. Iller, U. Kale, K. Lau, L. Green, and H. Wang J. Pharm. Biomed. Anal. 35 2004 65 73
29. K. Austin, A. Marshall, and H. Smith Nature 208 1965 999 1000
30. G. David, G. Harry, and R. Sudha Adv. Drug Deliv. Rev. 48 2001 3 26
31. E. Shefter, H. Fung, and O. Mok J. Pharm. Sci. 62 1973 791 794
32. H. Jun, S. Gupete, and R. Suryanarayanan Int. J. Pharm. 170 1998 63 72
33. S. Amid, and E. Richard Int. J. Pharm. 163 1998 157 166